Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

The Canadian Cancer Trials Group is very pleased to announce that the Intergroup melanoma trial, Canadian Cancer Trials Group MEC.3 (ECOG 1609) - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma - was centrally activated on October 1, 2012.

MEC.3 is a phase III randomized trial targeting a patient population that is at a high and unacceptable risk of recurrence and death after standard surgical management.

Patients with resectable high-risk deep cutaneous melanoma, patients with lymph node involvement by melanoma, patients with gross extra-nodal extension of disease, satellites, and/or in-transit lesions, as well as patients with completely resected stage IV disease, have the highest recurrence risk and the poorest disease-free and overall survival rates.

This trial is designed to evaluate the recurrence-free survival and overall survival of these patients. Once randomized, patients will be assigned to treatment with either high dose ipilimumab (Arm A), high dose interferon alfa - 2b (Arm B), or low dose ipilimumab (Arm C). All three arms will include an induction and maintenance phase of treatment.

For more information about this trial, please contact Chad Winch, Study Coordinator at 613-533-6430 or